BenevolentAI Investor Presentation Deck
Prioritising our high-value assets
5 DIFFERENTIATED ASSETS
Prioritises the Company's most advanced and high
potential assets, which were originated by our Al
platform, progressing them to their value inflection
points
HYBRID DEVELOPMENT MODEL
Retention of in-house core competencies,
combined with strategic outsourcing
ENHANCED CAPITAL ALLOCATION
Spend reduction through right-sized lab footprint,
and allocation of resources towards our
highest-potential assets
i PRIORITISED ASSETS
Chemistry & Lead Opt.
BEN-8744 | Ulcerative Colitis
BEN-28010 | Glioblastoma Multiforme
BEN-34712 | ALS
Parkinson's Disease
I
Pre-Clinical
Fibrosis
Other programmes are being paused; there will be no further spend
I on BEN-2293
Pre-Clinical
Ph. 1
Chemistry & Lead Opt.
Benevolent 10View entire presentation